欢迎来到天天文库
浏览记录
ID:32186904
大小:613.73 KB
页数:21页
时间:2019-02-01
《乌苯美司联合沙利度胺治疗复发难治性多发性骨髓瘤疗效观察》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库。
1、四、五、—L/、、目摘要中文论著摘要⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯英文论著摘要⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯英文缩略语⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯·-论文前言⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯5资料与方法⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯5结果⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯7讨论⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯1l结论⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯12本研究创新性的自我评价⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯13参
2、考文献⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯14附录综述⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯15致i9}⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯21个人简介⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯22·中文结构式摘要·乌苯美司联合沙利度胺治疗复的疗效观察目的探讨乌苯美司(Ubenimex)联合沙利度胺(thalidomide)治疗难治复发性多发性骨髓瘤的疗效及其应用价值。方法将复发难治的骨髓瘤患者分为3组。其中乌苯美司、沙利度胺VAD组1
3、3例,百士欣30mg晨起空腹口服,沙利度胺起始剂量50mg/d,每周递增50mg,至100-200mg/d,长春地辛4mg第一天,表柔比星10mg第一至四天,地塞米松20mg/d第一至四天;沙利度胺VAD组13例,沙利度胺及VAD用量用法同上;单用VAD组13例,用法同上。结果百士欣、沙利度胺VAD组治疗后较治疗前平均血红蛋白浓度升高8.1%,骨髓瘤细胞百分比下降73.9%,IgG下降59.1%,IgA下降75.1%;治疗前后比较,P值分别为O.58,4、VAD组与其他两组治疗后比较IgG和IgA含量均明显降低,P值均小于0.05,有统计学意。结论乌苯美司联合沙利度胺VAD方案能有效减轻复发难治性多发性骨髓瘤患者的骨髓瘤细胞负荷,降低血清M蛋白含量,总有效率优于单用沙利度胺联合VAD方案及单用VAD方案关键词乌苯美司,沙利度胺,难治复发性多发性骨髓瘤·英文论著摘要·UnitedUbenimexthalidomidetreatmentofrelapsedorrefractorymultiplemyelomacancerObjectiveToinvestig5、atetheUbenimexUnitedthalidomidetreatmentofrefractoryandrelapsedmultiplemyelomaanditsapplicationvalue.Methodsrelapsedorrefractorymyelomapatientsweredividedinto3groups.UbenimexthalidomideVADgroup13cases,Ubenimexoral30mgfastingmorning,startingdoseofthalidom6、ide50mg/d,aweeklyincreaseof50mg,from100-200mg/d,vindesine4mgthefirstdayofepirubicin10mgtothefirstfourdaysofdexamethasone20mg/dtothefirstfourdays;VADthalidomidegroup,13casesofthalidomideandVADusagedosageIbid;singleVADgroupwith13cases.theuseofibid.ResultsU7、benimexthalidomidegroupaftertreatmentthanbeforetreatmenttheaverage8.1percentincreaseinhemoglobinconcentration,percentageofmyelomacellsdecreased3.9%,IgGdropped59.1%,IgAdecreased75.1%;beforeandaftertreatmentmparison,Pvalueswere0.58,<0.01,0.037,0.014.Ubenim8、exthalidomidegroupandtheothertwogroupsaftertreatmentcomparedIgGandIgAlevelsweresignificantlylower,P<0.05.thereisstatisticalsignificance.ConclusionUbenimexthalidomideVADprogramCaneffectivelyreducetherelapsedorrefractorymult
4、VAD组与其他两组治疗后比较IgG和IgA含量均明显降低,P值均小于0.05,有统计学意。结论乌苯美司联合沙利度胺VAD方案能有效减轻复发难治性多发性骨髓瘤患者的骨髓瘤细胞负荷,降低血清M蛋白含量,总有效率优于单用沙利度胺联合VAD方案及单用VAD方案关键词乌苯美司,沙利度胺,难治复发性多发性骨髓瘤·英文论著摘要·UnitedUbenimexthalidomidetreatmentofrelapsedorrefractorymultiplemyelomacancerObjectiveToinvestig
5、atetheUbenimexUnitedthalidomidetreatmentofrefractoryandrelapsedmultiplemyelomaanditsapplicationvalue.Methodsrelapsedorrefractorymyelomapatientsweredividedinto3groups.UbenimexthalidomideVADgroup13cases,Ubenimexoral30mgfastingmorning,startingdoseofthalidom
6、ide50mg/d,aweeklyincreaseof50mg,from100-200mg/d,vindesine4mgthefirstdayofepirubicin10mgtothefirstfourdaysofdexamethasone20mg/dtothefirstfourdays;VADthalidomidegroup,13casesofthalidomideandVADusagedosageIbid;singleVADgroupwith13cases.theuseofibid.ResultsU
7、benimexthalidomidegroupaftertreatmentthanbeforetreatmenttheaverage8.1percentincreaseinhemoglobinconcentration,percentageofmyelomacellsdecreased3.9%,IgGdropped59.1%,IgAdecreased75.1%;beforeandaftertreatmentmparison,Pvalueswere0.58,<0.01,0.037,0.014.Ubenim
8、exthalidomidegroupandtheothertwogroupsaftertreatmentcomparedIgGandIgAlevelsweresignificantlylower,P<0.05.thereisstatisticalsignificance.ConclusionUbenimexthalidomideVADprogramCaneffectivelyreducetherelapsedorrefractorymult
此文档下载收益归作者所有